• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: New insights into caring for pediatric patients with cystic fibrosis.

作者信息

Bui Stephanie, Delhaes Laurence, Dournes Gael, Reix Philippe, Fayon Michael John

机构信息

Paediatric Cystic Fibrosis Reference Center (CRCM), Bordeaux University Hospital, Hôpital Pellegrin-Enfants, Bordeaux, France.

Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, CIC 1401, Bordeaux University Hospital, Bordeaux, France.

出版信息

Front Pediatr. 2023 Aug 9;11:1243496. doi: 10.3389/fped.2023.1243496. eCollection 2023.

DOI:10.3389/fped.2023.1243496
PMID:37635799
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10450029/
Abstract
摘要

相似文献

1
Editorial: New insights into caring for pediatric patients with cystic fibrosis.社论：对囊性纤维化儿科患者护理的新见解
Front Pediatr. 2023 Aug 9;11:1243496. doi: 10.3389/fped.2023.1243496. eCollection 2023.
2
Benefits of newborn screening for cystic fibrosis in Shreveport, Louisiana, Cystic Fibrosis Center.路易斯安那州什里夫波特囊性纤维化中心新生儿囊性纤维化筛查的益处。
J La State Med Soc. 2011 Nov-Dec;163(6):316-9.
3
Cystic fibrosis newborn screening: Five-year experience from a tertiary care center.囊性纤维化新生儿筛查：来自一家三级护理中心的五年经验。
Pediatr Pulmonol. 2022 Feb;57(2):403-410. doi: 10.1002/ppul.25778. Epub 2021 Dec 7.
4
Evaluation of specificity and sensitivity of IRT/IRT protocol in the cystic fibrosis newborn screening program: 6-year experience of three tertiary centers.IRT/IRT方案在囊性纤维化新生儿筛查项目中的特异性和敏感性评估：三个三级中心的6年经验
Eur J Pediatr. 2023 Mar;182(3):1067-1076. doi: 10.1007/s00431-022-04766-4. Epub 2022 Dec 24.
5
Implementing a tracking system for confirmatory diagnostic results after positive newborn screening for cystic fibrosis-implications for process quality and patient care.实施针对囊性纤维化阳性新生儿筛查后确诊诊断结果的跟踪系统-对流程质量和患者护理的影响。
Eur J Pediatr. 2021 Apr;180(4):1145-1155. doi: 10.1007/s00431-020-03849-4. Epub 2020 Oct 26.
6
Cost effectiveness of newborn screening for cystic fibrosis: a simulation study.新生儿囊性纤维化筛查的成本效益：一项模拟研究。
J Cyst Fibros. 2014 May;13(3):267-74. doi: 10.1016/j.jcf.2013.10.012. Epub 2013 Nov 12.
7
The benefits of newborn screening for cystic fibrosis: The Canadian experience.新生儿囊性纤维化筛查的益处：加拿大的经验。
J Cyst Fibros. 2016 May;15(3):302-8. doi: 10.1016/j.jcf.2016.04.001. Epub 2016 Apr 21.
8
Two years of newborn screening for cystic fibrosis in Turkey: Çukurova experience.土耳其两年新生儿囊性纤维化筛查：Çukurova地区的经验。
Turk J Pediatr. 2019;61(4):505-512. doi: 10.24953/turkjped.2019.04.006.
9
Current Status of Genetic Diagnosis Laboratories and Frequency of Genetic Variants Associated with Cystic Fibrosis through a Newborn-Screening Program in Turkey.土耳其一项新生儿筛查计划中的遗传诊断实验室现状和与囊性纤维化相关的遗传变异频率。
Genes (Basel). 2021 Jan 31;12(2):206. doi: 10.3390/genes12020206.
10
Differences in clinical condition and genotype at time of diagnosis of cystic fibrosis by newborn screening or by symptoms.通过新生儿筛查或症状诊断囊性纤维化时临床状况和基因型的差异。
Mol Genet Metab. 2014 Sep-Oct;113(1-2):100-4. doi: 10.1016/j.ymgme.2014.07.012. Epub 2014 Jul 16.

本文引用的文献

1
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study.依伐卡托钠/泰比卡托钠/埃他卡托钠在 和最小功能突变杂合子且年龄在 6 至 11 岁的囊性纤维化儿童中的疗效和安全性：一项 3b 期、随机、安慰剂对照研究。
Am J Respir Crit Care Med. 2022 Dec 1;206(11):1361-1369. doi: 10.1164/rccm.202202-0392OC.
2
Long-Term Outcomes in Real Life of Lumacaftor-Ivacaftor Treatment in Adolescents With Cystic Fibrosis.鲁马卡托-依伐卡托治疗青少年囊性纤维化的现实生活长期结局
Front Pediatr. 2021 Nov 15;9:744705. doi: 10.3389/fped.2021.744705. eCollection 2021.
3
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.依伐卡托/泰它卡托/艾氟卡托治疗囊性纤维化的临床疗效：一项临床试验。
Am J Respir Crit Care Med. 2022 Mar 1;205(5):529-539. doi: 10.1164/rccm.202108-1986OC.
4
Real-world assessment of LCI following lumacaftor-ivacaftor initiation in adolescents and adults with cystic fibrosis.在青少年和成年囊性纤维化患者中，在起始使用 lumacaftor-ivacaftor 后进行真实世界评估 LCI。
J Cyst Fibros. 2022 Jan;21(1):155-159. doi: 10.1016/j.jcf.2021.06.002. Epub 2021 Jun 26.
5
Cystic fibrosis in the year 2020: A disease with a new face.2020年的囊性纤维化：面貌一新的疾病。
Acta Paediatr. 2020 May;109(5):893-899. doi: 10.1111/apa.15155. Epub 2020 Jan 22.
6
Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis.真实世界中 Lumacaftor-Ivacaftor 治疗囊性纤维化患者的安全性和有效性。
Am J Respir Crit Care Med. 2020 Jan 15;201(2):188-197. doi: 10.1164/rccm.201906-1227OC.
7
The changing epidemiology and demography of cystic fibrosis.囊性纤维化不断变化的流行病学和人口统计学特征。
Presse Med. 2017 Jun;46(6 Pt 2):e87-e95. doi: 10.1016/j.lpm.2017.04.012. Epub 2017 May 26.
8
[New therapeutic developments in cystic fibrosis].
Arch Pediatr. 2016 Dec;23(12S):12S47-12S53. doi: 10.1016/S0929-693X(17)30062-3.
9
Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation.囊性纤维化的诊断：来自囊性纤维化基金会的共识指南
J Pediatr. 2017 Feb;181S:S4-S15.e1. doi: 10.1016/j.jpeds.2016.09.064.
10
Year to year change in FEV in patients with cystic fibrosis and different mutation classes.囊性纤维化患者及不同突变类型患者的第一秒用力呼气容积逐年变化。
J Cyst Fibros. 2017 Mar;16(2):239-245. doi: 10.1016/j.jcf.2016.09.009. Epub 2016 Oct 11.